Tarsus Pharmaceuticals, Inc.
TARS· Nasdaq
Released Aug 5, 2026, after the close
10-Q filed Aug 6, 2026, 37 days after period end · 0001819790-26-000064
| Metric | Q2 2026 | Q2 2025 | Q2 2024 | Q2 2023 |
|---|---|---|---|---|
| Revenue | $173.91M | $102.66M | $40.81M | $0.00 |
| Net Income | -$18.55M | -$20.34M | -$33.29M | -$31.42M |
| EPS Diluted |
Tarsus Pharmaceuticals, Inc. · CIK 1819790 · Engraved from SEC EDGAR
| -$0.43 |
| -$0.48 |
| -$0.88 |
| -$1.17 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.